On November 15, 2022, the FDA approved a drug that works like a guided missile. Mirvetuximab soravtansine, sold as Elahere, targets a specific protein found on certain cancer cells and delivers a potent toxin directly inside them. It is not a broad chemotherapy. It is a first-in-class medication, the agency said.
The drug is built for a narrow fight. It treats epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer — but only in patients whose tumors overexpress a protein called folate receptor alpha. That marker matters. Without it, the drug has nothing to lock onto.
This is a conjugate. One half is an antibody that hunts the folate receptor. The other half is a microtubule inhibitor, a type of poison that stops cancer cells from dividing. The two are chemically linked. The idea is precision: spare healthy tissue, hit the tumor hard.
It took years to get here. The development of mirvetuximab soravtansine involved clinical trials testing safety and efficacy in women who had already tried other treatments. Many had limited options left. The FDA approval opens a new path for them.
But the drug is not without cost. The most common side effects include vision impairment, fatigue, nausea, and keratopathy — damage to the cornea. Patients also report abdominal pain, diarrhea, and peripheral neuropathy. Lab work often shows elevated liver enzymes and decreased lymphocyte counts. These are not trivial. They require monitoring.
The approval signals a shift in how cancer drugs are designed. Rather than carpet-bombing the body, researchers are building therapies that exploit molecular signatures unique to tumors. Folate receptor alpha is overexpressed in a significant subset of ovarian cancers. That made it a target worth pursuing.
Ovarian cancer is notoriously difficult to catch early. It often spreads before symptoms appear. Fallopian tube cancer and primary peritoneal cancer share similar biology and are treated similarly. The new drug applies to all three.
The FDA’s decision came after a review of data showing tumor shrinkage in a group of patients who had progressed on prior therapy. The response rate was not universal, but for those who responded, the effect was meaningful. The agency granted accelerated approval, a pathway used for drugs that fill an unmet medical need.
Mirvetuximab soravtansine is the result of decades of research into antibody-drug conjugates. The concept has been tried before with varying success. This one works differently. It uses a cleavable linker designed to release the toxin only once inside the cancer cell. That reduces systemic exposure.
Side effects remain a concern. Vision problems are especially notable. Patients may experience blurred vision, dry eyes, or photophobia. Regular eye exams are recommended. The fatigue can be profound. Nausea is common but manageable with antiemetics.
The approval happened in late 2022, but the story is older. Early trials began years earlier. The drug’s journey through the FDA involved multiple discussions about trial design, patient selection, and safety monitoring. The result is a treatment that is not for everyone — only for those whose tumors carry the right marker.
Testing for folate receptor alpha is now part of the treatment pathway. Patients must have their tumor tissue analyzed before receiving Elahere. That biomarker requirement is becoming more common in oncology. It reflects a broader move toward personalized medicine.
The drug is given intravenously every three weeks. It is not a cure. It is a tool. For some women, it may extend life or improve quality of life. For others, side effects may limit its use. The balance between benefit and risk is individual.
Mirvetuximab soravtansine is now on the market. The question that follows any new cancer drug is how it will perform in the real world, outside the controlled conditions of a trial. That answer will come with time.
